Loading...

World-Class Retina Care. Community-Based Caring.

Dr. Abbey Doses First Patient in Phase 1b/2a LOTUS-2 Clinical Trial of Novel Multivalent Fusion Antibody EB-105 for Diabetic Macular Edema

Posted On November 6, 2025 / By / Posted in Blog

Dr. Abbey Doses First Patient in Phase 1b/2a LOTUS-2 Clinical Trial of Novel Multivalent Fusion Antibody EB-105 for Diabetic Macular Edema

On October 28, 2025, Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, dosed the first patient in the Phase 1b/2a LOTUS-2 clinical trial of novel multivalent fusion antibody (EB-105) for diabetic

read more